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Background: The early drug discovery phase in pharmaceutical research and development marks the beginning of
a long, complex and costly process of bringing a new molecular entity to market. As such, it plays a critical role in
helping to maintain a robust downstream clinical development pipeline. Despite its importance, however, to our
knowledge there are no published in silico models to simulate the progression of discrete virtual projects through a
discovery milestone system.
Results: Multiple variables were tested and their impact on productivity metrics examined. Simulations predict that
there is an optimum number of scientists for a given drug discovery portfolio, beyond which output in the form of
preclinical candidates per year will remain flat. The model further predicts that the frequency of compounds to
successfully pass the candidate selection milestone as a function of time will be irregular, with projects entering
preclinical development in clusters marked by periods of low apparent productivity.
Conclusions: The model may be useful as a tool to facilitate analysis of historical growth and achievement over
time, help gauge current working group progress against future performance expectations, and provide the basis
for dialogue regarding working group best practices and resource deployment strategies.Background
Over the past fifteen years, productivity of pharmaceut-
ical research and development (R&D) in terms of
launched new molecular entities (NME) has at best been
flat while costs have risen, resulting in a sharp decline in
the number of first-in-class drugs entering the market as
a percentage of R&D expenditures [1,2]. Adoption of
new technologies, six sigma initiatives [3,4] and adaptive
clinical trial designs [5,6] have led to incremental
improvements, but the productivity challenge facing the
pharmaceutical industry as a whole remains. Although
studies in this area largely focus on the clinical develop-
ment aspect of the pipeline, a steady supply of quality
preclinical drug candidates must be maintained at the
front end to prevent downstream gaps from forming.
For example, shifting the focus from late stage phase III
studies to early clinical proof of concept (POC) would
require an abundance of preclinical candidate com-
pounds that both add projected value to the company’s
portfolio and have a reasonable probability of technical
success.Correspondence: melvin_yu@eisai.com
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reproduction in any medium, provided the orThe study by Paul and co-workers1 indicates that the
lead optimization phase of drug discovery contributes
significantly toward the out-of-pocket cost per launch of
an NME. Yet, despite the importance of the discovery
phase in pharmaceutical R&D, studies are lacking in the
literature to provide guidance regarding the optimal dis-
tribution of scientific resources to generate a sufficient
quantity of preclinical candidate compounds at a rate
that would lead to an NME entering the marketplace in
a specific time-frame. While particular sub-milestones
and milestone names may vary between the major
pharmaceutical companies, the primary transition and
go/no-go decision points for the early drug discovery
pipeline can be categorized as those depicted in
Figure 1.
Attrition rates for compounds as they move through
the milestone system have been published1 and could be
used to approximate the average percent success rate of
projects transitioning from one stage to the next. The
question that we asked was whether this information
could be employed to derive useful guidelines for human
resource distribution by scientific discipline, and what
the optimal number of chemists and biologist might beis is an Open Access article distributed under the terms of the Creative
commons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Diagram of major milestone transition and go/no-go
decision points in the discovery phase of pharmaceutical R&D
leading to preclinical development. Details as follows: (1) Conduct
exploratory work that includes project conception, target validation
and screening. (2) Identify chemical lead(s) and establish target drug
profile. (3) Optimize chemical properties and biological activity
against the target drug profile. (4) Complete all necessary studies to
allow an investigational new drug (IND) application to be filed.
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under a specific set of conditions.
Although a number of simulation and game theory
algorithms have been used in clinical development mod-
els, [7] to our knowledge there are no published in silico
models that simulate the progression of projects through
early discovery, i.e. from conceptualization to candidate
selection. Given the importance of the discovery phase
to pharmaceutical R&D, we developed a Monte Carlo
simulation algorithm for modeling discrete virtual pro-
jects as they move through the discovery milestone sys-
tem ending with entry into preclinical development.
Each virtual project has associated with it a dynamic
number of chemists and biologists with drug metabol-
ism/pharmacokinetics (DMPK) support that varies
according to project priority, type, and milestone stage.
Such an in silico model would allow multiple variables
to be evaluated for a given portfolio of drug discovery
programs in the context of expected productivity
metrics.
Methods
With scientific specialization comes the need for cross-
functional teams [8]. Pharmaceutical R&D is no excep-
tion. For purposes of the model, however, a simplifying
assumption is made that drug discovery project teams
consist of medicinal/synthetic chemists, biologists cap-
able of developing and running multi-tiered in vitro
assay systems and relevant in vivo animal models as well
as representation by members of the DMPK group.
While scientists from a number of specialized scientific
disciplines (e.g. process chemistry research, analytical
chemistry, computational chemistry, biopharmaceutical
assessment, formulation, in vivo imaging, etc.) partici-
pate to varying degrees in the drug discovery process,
their roles are assumed not to be rate limiting with re-
gard to decision-making until projects approach the pre-
clinical development go/no-go decision point. Cost and
other considerations often limit, for example, either pre-
clinical animal multispecies allometric scaling or in silico
simulations that use experimental in vivo and in vitro
data to derive human drug exposure and dose projectionvalues. Since these studies are usually, if not exclusively,
performed on candidate compounds and not during the
early phase of drug discovery, we assume for purposes of
the model that chemistry, biology and discovery DMPK
represent the rate limiting scientific disciplines during
early discovery, depending on the scientific issues to be
addressed. Although data generated by the other specia-
lized disciplines are certainly used by project teams to
help guide a structure-activity relationship (SAR) investi-
gation, the model assumes that there is enough resource
support from the ancillary disciplines to allow decisions
to be made within the discovery cycle times specified by
the user.
The algorithm takes as input a series of user-defined
numbers that describes a typical project at the hit to lead
and lead optimization stages. This includes a target
number of chemists and biologists, cycle time, milestone
transition probabilities, and project type. Project type in-
clude those that are biology-driven (i.e., projects that
typically involve high-throughput screening (HTS)
against a biological target of interest), and those that are
chemistry-driven with a clearly identified chemical lead,
but not necessarily information about mechanism of ac-
tion (MOA). In either case, the link between MOA and
human disease may or may not be established. Another
type of project are those that are “follow-on” or “back-
up” projects that share biological resources and thera-
peutic target with another on-going discovery program,
albeit with a different structural scaffold or chemical
lead. In such cases, the SAR will likely diverge from its
related project, and will, if successful, afford a candidate
compound with a similar drug profile, but with a differ-
ent scaffold and therefore a different set of physico-
chemical properties. The algorithm treats the two as
separate and distinct projects, albeit with different levels
of chemical and biological support, whose outcome
could both lead to preclinical candidate compounds.
The user has the ability to specify the percent of projects
that are “follow-on” and the percent of those that are
chemistry versus biology driven (Figure 2).
Since project cycle time is dependent on the level of
resource support, a simple monotonic function was used
to correct the time to milestone decision. For example,
the algorithm may allow a project at the hit to lead stage
to reach lead optimization in one year if fully staffed, but
would correct that value to two years if only half-staffed.
If additional resources become available in-between the
hit to lead and lead optimization stages, then the time to
milestone decision would be adjusted according to
Equation 1. In this fashion, project cycle times are
linearly dependent on the level of staffing up to the tar-
get number of chemists or biologists. The total number
of scientists on the project team is not allowed to exceed
the target value specified by the user. For hit to lead
Figure 2 Algorithm flow chart that spans project ideation
(exploratory) to candidate selection for project type (hit to
lead) and priority (lead optimization).
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ability of success defined by the original random number
assigned at the time it transitioned from exploratory.
Maximum staffing levels for all hit to lead projects are
calculated using Equation 2.
The full time equivalent (FTE) efficiency parameter as
defined by the model is the fractional amount of time
spent on direct project related activities not including,
for example, recruiting, general training, scientific con-
ferences, meetings, etc., and is a function of group size
(vide infra).
A ¼ CT TCþ TBð Þ
F• Cþ Bð Þ ð1Þ
Updated TD ¼ A TE•A
old TD
Where the following definitions apply:
CT = cycle time to next milestone
TC = target no. chemists for project at current
milestone
TB = target no. biologists for project at current
milestone
F = FTE efficiency
C = updated no. chemists assigned to the projectB = updated no. biologists assigned to the
project
TE = time elapsed since last milestone transition
TD = time to next milestone go/no-go decision
max ¼ ceiling r·s=tð Þ ð2Þ
Where:
r = random number (0 ≤ r < 1) assigned at time of
transition from screening (i.e., exploratory) to hit to lead
s = target no. chemists/biologists at hit to lead stage
t = threshold for successfully transitioning from ex-
ploratory to hit to lead
max = maximum number of chemists/biologists
that can be assigned to this particular hit to lead project.
If r = 0, then only the default number of biologists and
chemists can assigned to the project.
Virtual projects are created and progress through the
drug discovery pipeline by successfully passing a series
of go/no-go decision points based on a random number
assignment and comparison against the user specified
probability of success threshold for the particular mile-
stone transition. If the random number is below the
threshold, then the project successfully transitions to the
next milestone. If not, then the project is terminated and
scientists are reassigned to other activities as described
below. For example, if a screening project is ready to
progress to hit to lead, a random number is generated. If
that number is less than the threshold value for moving
to the next milestone, then the project is considered to
have successfully transitioned to the hit to lead phase.
By default, the project is then staffed by one chemist
and one biologist. The random number also represents
that hit to lead project’s priority, which is then used to
calculate the maximum number of additional chemists
or biologists that can be added to the project (Equation 2).
To illustrate the point, if the target number of hit to
lead biologists is 3, the random number is 0.5 and the
threshold value is 0.8, then that hit to lead project can
only be staffed with a maximum of 2 biologists. In other
words, only one additional biologist can be added on
top of the original default number of 1. If the random num-
ber is zero, then no additional biologists can be added.
In this manner, hit to lead projects are resourced com-
mensurate with their assigned priority. Hit to lead pro-
ject progression to lead optimization proceeds in a
similar manner. However, if the transition is successful all
attempts are made to fully staff the project as defined
by the user. Projects at the lead optimization stage can
also receive DMPK support, which effectively acts to ac-
celerate SAR decision-making (and consequently com-
press the time to next milestone) by allowing analogues
with poor in vivo exposure to be identified as early as
possible. In this manner cycle times can be reduced.
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decisions are rendered based on scientific merit that
takes into account compound druggability and physico-
chemical properties.
Scientists are released for reassignment when their
project experiences the following: (a) failure to pass a
milestone and is terminated, (b) temporarily put on hold
to free resources for a high priority lead optimization
campaign or (c) successfully enters preclinical develop-
ment. The order of reassignment is first, to on-going
understaffed lead optimization projects, second, to re-
staff any hit to lead projects that were put on hold, third
to on-going understaffed hit to lead activities, and
fourth, to new project ideation and generation (explora-
tory projects) as outlined in Figure 3. New project activ-
ities include biological target identification, validation
and compound library screening or in the case of
chemistry-driven programs, identification of a chemical
starting point through professional contacts (e.g. aca-
demic collaborations, strategic alliances, in-licensing,
etc.), scientific conferences or the literature. Projects are
considered understaffed if the number of assigned che-
mists and biologists is below their target values. As is
true in many large pharmaceutical companies, the modelFigure 3 Decision flow chart of project milestone progression
and scientist reassignment priority. Assignment of scientists to hit
to lead projects is first to those on hold (if any) and second to any
on-going understaffed efforts.assumes that all scientists spend a percentage of their
time pursuing exploratory activities in addition to their
primary project responsibilities. Any scientist not
assigned to a specific milestone project is considered to
be working on these type of activities. As a result, the
model does not track discrete exploratory efforts, but ra-
ther assumes an excess of ideas relative to the number
of scientists, i.e., that there are more research proposals
to work on than time or resources will allow.
The algorithm allows for the successful transition of
hit to lead projects into two types of lead optimization
campaigns: high priority and standard priority (Figure 2).
For high priority projects, the algorithm first reassigns
scientists working on exploratory efforts. If fully staffing
the project team is not possible, then the algorithm will
selectively terminate hit to lead projects starting with
those that are the least supported. If full staffing is still
not possible despite terminating all hit to lead projects
and diverting effort from all exploratory activities, then
the project is still allowed to transition. Additional scien-
tists are added as they become available. For standard
priority lead optimization campaigns the staffing level is
maintained from its hit to lead level and scientists are
added to the project team as availability allows. In both
instances, the time to milestone go/no-go decision is
adjusted accordingly. The ratio between these two types
of projects is user-defined and will depend on individual
company strategy, policies and procedures.
A working group is defined by the model as an
organizational structure comprised of scientists in a sin-
gle cross-functional unit such as a department, division,
or center that targets a specific therapeutic area or sub-
specialty (e.g., obesity within metabolic disorders could
be considered a working group). As used by the model,
the scientists within the working group support a num-
ber of different individual projects with varying degrees
of staffing at different points along the drug discovery
pipeline. In other words, members of a working group
(i.e., unit, department, division, or center – different com-
panies use different names) work to support multiple dis-
covery project teams. Since there will likely be multiple
working groups, each supporting multiple projects,
within a large organization, the model would consider
each of these units as essentially autonomous, i.e., oper-
ating largely independent of one another in a managerial
and budgetary sense. Of course, some degree of commu-
nication and cooperation between the therapeutic and
specialty units in a larger organization must take place
for synergy and process gains to occur, and for shared ex-
perience and tacit scientific knowledge to drive the cor-
porate knowledge creation spiral [9,10].
In the absence of appropriate constraints, however,
there would be an unbounded linear relationship be-
tween preclinical drug candidate output and group size,
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fashion (Figure 4). Published studies, [11,12] anecdotal
evidence, [13] and intuition, on the other hand, do not
support the possibility of infinite growth as either realis-
tic or even desirable, particularly with regard to early
discovery (e.g., project ideation) and decision-making
[14,15] While at its most basic, Condorset’s jury theorem
might suggest that as group size approaches infinity, the
probability of a correct decision (e.g., go/no-go mile-
stone decision) approaches one given ρ is greater than
0.5 [16,17]. However, the theorem assumes that all mem-
bers cast their vote independent of one another with
uniform probabilities. Although the theorem has since
been generalized, [18] mutual independence would
clearly not be an optimal arrangement for scientists ei-
ther within a cross-functional project team or in the lar-
ger working group charged with such decisions.
Typically, in advance of the actual decision-making
event reports must be prepared and meetings held in
order to communicate results and ensure adequate
understanding of the key issues. Here the objective is a
consensus decision through opinion aggregation, [19]
rather than a simple majority vote. Thus, as group size
increases FTE “overhead” must also increase due to the
exponential rise in the amount of correspondence, num-
ber of progress reports that must be written and read as
well as the need for greater managerial oversight that
may include multiple lines of reporting, especially in the
case of global discovery project teams [20]. In large
pharmaceutical companies, for example, scientists are
typically subdivided into cross-discipline specialty cen-
ters, units, departments or divisions to create more
manageable, functional sized, and focused working
groups. A correction factor was therefore needed toFigure 4 Relationship between number of chemists, number of
biologists and output defined by the average number of
preclinical candidate compounds per year.mathematically relate productivity to FTE efficiency as a
function of working group size. Paramount to this is the
ability of working group members to make the most
informed decisions in a timely manner, [21,22] since that
lies at the heart of project progression through a drug
discovery milestone system.
Unfortunately, publications in this area primarily ad-
dress single, relatively small teams of less than 10–20
people that do not interact with other teams as part of a
larger working unit [23] We therefore needed a general
way to quantitate efficiency as a function of group size
in the context of multiple project teams. To accomplish
this, we propose using a modified equation based on the
diffusion of innovations theory popularized by Rogers,
[24] which posits that individuals progress through five
stages before adopting a new innovation or technology:
knowledge, persuasion, decision, implementation, and
confirmation. If we assume that a research group consti-
tutes a type of social system, then communication in its
many forms represents a critical factor that influences
how new ideas become reduced to practice and recog-
nized as a formal project through formation of a discov-
ery project team. Decision-making becomes increasingly
difficult, time-consuming and complex as working group
size increases, particularly if there is a range of expertise
in the group. In that sense, efficiency as defined by time
spent on specific project related activities must be in-
versely proportional to the amount of time discovery
project teams must spend dealing with bureaucracy [25]
in its many forms. Just as diffusion of innovations fol-
lows a logistic curve, we propose that FTE efficiency as a
function of working group size must follow a similar
path, but with a positive Euler’s exponent (Equation 3
where x is group size, E(x) is efficiency as a function of
group size, and parameters A and B define the decay
rate and inflection point, respectively). In this manner,
efficiency exponentially decreases as working group size
increases, asymptotically approaching zero as group size
approaches infinity.
E xð Þ ¼ 1
1þ e xABð Þ
ð3Þ
where E is FTE efficiency, x is group size, A and B are
positive, non-zero parameters.
From Equation 3, efficiency equals 0.5 when group size
equals the product of parameters A and B. However,
since A and B are abstract values and therefore difficult
to assign a priori, another form of the equation was
derived. Two alternative parameters, M and N, were
defined as the group size with 50% and 75% FTE effi-
ciency, respectively. Substituting into Equation 3, re-
arranging, and solving for parameter A yields Equation 4.
The value for B was obtained by simple rearrangement.
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then affords Equation 5. The parameters M and N are
under user control and can thus be adjusted depending
on individual company culture, accepted communica-
tion norms, organizational structure (e.g., degree of







where M = group size operating at 50% efficiency and
N = group size operating at 75% efficiency. In all
cases, M>N.
E xð Þ ¼ 1
1þ e 1:1 xMð ÞMNð Þ
ð5Þ
Where x is group size and E(x) is FTE efficiency as
a function of group size. M and N are defined in
Equation 4.
The user now only needs to estimate the ratio of time
spent by scientists on direct project related activities
versus other responsibilities for a given group size in
order to calculate the FTE efficiency curve. It is expected
that these estimates would vary across companies or even
across individual working groups operating within a
larger organization.
The Monte Carlo simulation algorithm was written
in C and compiled using a GNU C compiler for exe-
cution on a Windows platform (please contact the au-
thor for a copy of the source code and accompanying
control file). At present there is no GUI associated
with the computer program. Rather, simulation para-
meters and other control values are entered through a
simple tab-delimited text file. At some future point, a
front-end GUI may be constructed to make the pro-
gram more user-friendly.
Experimental
To run the program, the user must first enter control
parameter values into a simple tab-delimited text file.
Upon launch, the program reads the file whose para-
meters are defined below:
Probability of achieving Hit to Lead milestone
Probability that an exploratory effort will successfully
(1) develop a multi-tiered evaluation system for com-
pound screening against a validated biological target,
and (2) identify active hit compounds (range 0–1).
Probability of achieving Lead Optimization milestone
Probability that a hit to lead project will successfully
(1) identify an optimizable lead series of compounds,
and (2) define a target drug profile (range 0–1).Probability of achieving Preclinical Development
milestone
Probability that a lead optimization campaign will suc-
cessfully identify a preclinical candidate compound that
satisfies the target drug profile criteria (range 0–1).
Percentage of follow-on Hit to Lead projects
Percentage of hit to lead projects that share a common
biological target with another on-going project, but with
a different scaffold or lead series (range 0–0.5).
Percentage of chemistry-driven Hit to Lead projects
Percentage of hit to lead projects that involve a spe-
cific compound or compound series whose MOA may
or may not be known. The balance of hit to lead projects
are assumed to have arisen through HTS involving a
validated biological target (range 0–1).
Percentage of prioritized Lead Optimization projects
Percentage of lead optimization projects that will be
designated as high priority. The balance of lead
optimization projects will be assigned standard priority
(range 0–1).
Target no. Hit to Lead CHEMISTS (chemistry-driven)
per team
Target number of chemists that will be assigned to a
chemistry-driven hit to lead project (integer>0).
Target no. Hit to Lead BIOLOGISTS (chemistry-driven)
per team
Target number of biologists that will be assigned to a
chemistry-driven hit to lead project (integer>0).
Target no. Hit to Lead CHEMISTS (biology-driven) per
team
Target number of chemists that will be assigned to an
HTS directed hit to lead project (integer>0).
Target no. Hit to Lead BIOLOGISTS (biology-driven)
per team
Target number of biologists that will be assigned to an
HTS directed hit to lead project (integer>0).
Target no. Hit to Lead CHEMISTS (follow-on) per team
Target number of chemists that will be assigned to a
follow-on type of hit to lead project (integer>0).
Target no. Hit to Lead BIOLOGISTS (follow-on) per
team
Target number of biologists that will be assigned to a
follow-on type of hit to lead project (integer>0).
Target no. Lead Optimization CHEMISTS per team
Target number of chemists that will be assigned to a
lead optimization project (integer>0).
Target no. Lead Optimization BIOLOGISTS per team
Target number of biologists that will be assigned to a
lead optimization project (integer>0).
No. simultaneous lead optimization projects supported
by DMPK
Maximum number of discovery projects that can be
supported simultaneously by the DMPK group
(integer≥0).
Figure 5 FTE efficiency curve generated by Equation 5 with
M=40 and N=20.
Figure 6 Transition probability matrix for the discovery
milestone system using values reported by Paul and co-
workers1.
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Percent shortening of timeline if DMPK support is
present (range 0–1).
Target cycle time (months) to achieve Lead
Optimization
Project cycle time from hit to lead to lead optimization
(integer>0).
Target cycle time (months) to achieve Preclinical
Development
Project cycle time from lead optimization to candidate
selection (integer>0).
Group size at 75% FTE efficiency
Estimated working group size where each member
spends approximately 75% of their time on direct project
related activities. This will depend on company culture,
corporate policies and how direct project related activ-
ities are defined by the user (integer>0).
Group size at 50% FTE efficiency
Estimated working group size where each member
spends approximately 50% of their time on direct project
related activities. This group size value must be greater
than the one for 75% FTE efficiency (integer>0).
Additional parameters include those for defining the
total number of chemists and biologists that comprise
the working group to be simulated, the time period for
data collection, and the number of replicate runs. The
user also has the ability to override the FTE efficiency
calculation and enter a static value (e.g., 1 for 100% FTE
efficiency regardless of working group size). An example
list of parameter values can be found in the Results and
Discussion section.
Upon completion of the run, a text file is created that
contains the predicted average number of preclinical
candidates per year in a single column format. This can
be converted to a matrix form using a variety of com-
mercial software packages (e.g., OriginPro [26]) and the
results displayed as either a two- or three-dimensional
plot.
Results and discussion
A possible starting approximation is that FTE efficiency
is 75% when the size of a single working group (i.e., de-
partment, division or specialty center) of scientists
approaches 20 and may be projected to be 50% when
that number reaches 40. Entering those starting esti-
mates into Equation 5 as parameters N and M, respect-
ively, affords the FTE efficiency curve shown in Figure 5.
The percent technical success criteria reported by Paul
and co-workers1 for compounds to reach the hit to lead,
lead optimization, preclinical development and clinical
development milestones are 80%, 75%, 85%, and 69% re-
spectively. Thus, the milestone system with observed
transition probabilities could be considered a simple
Markov chain with a transition probability matrix asshown in Figure 6. Applying those values to percent pro-
ject success thresholds along with the simulation para-
meters summarized in Table 1 provided the result
illustrated in Figure 7.
Under these assumptions, the optimum total number
of scientists in a working group is predicted by the
model to be around 36 (18 chemists, 18 biologists and
sufficient DMPK support to allow decisions to be made
within the published cycle times) with an expected aver-
age output of 0.86 preclinical candidates per year. The
pharmaceutical R&D productivity model proposed by
Paul and coworkers1 indicates that approximately 11
small molecule compounds must enter clinical develop-
ment to afford 1 NME launch every year. Taken to-
gether, our Monte Carlo model predicts that an
organization aspiring to produce a minimum of 1 NME
launch per year would need 12–13 working groups of
that size or its equivalent output in the form of strategic
alliances, mergers or acquisitions to meet its annual
productivity objective. While these numbers would be
expected to vary across companies, the modeling results
do allow users within a company to assess the impact
that project portfolio as well as working group size
might have on expected output. Since these projections
are a function of the simulation parameters specified by
the user, they will change depending on the values
entered.
Table 1 Parameters used in simulationa
Probability of achieving Hit to Lead milestone 0.80
Probability of achieving Lead Optimization milestone 0.75
Probability of achieving Preclinical Development milestone 0.85
Percentage of follow-on Hit to Lead projects 0.25
Percentage of chemistry-driven Hit to Lead projects 0.5
Percentage of prioritized Lead Optimization projects 0
Target no. Hit to Lead CHEMISTS (chemistry-driven) per team 2
Target no. Hit to Lead BIOLOGISTS (chemistry-driven) per team 3
Target no. Hit to Lead CHEMISTS (biology-driven) per team 1
Target no. Hit to Lead BIOLOGISTS (biology-driven) per team 3
Target no. Hit to Lead CHEMISTS (follow-on) per team 2
Target no. Hit to Lead BIOLOGISTS (follow-on) per team 1
Target no. Lead Optimization CHEMISTS per team 4
Target no. Lead Optimization BIOLOGISTS per team 4
No. simultaneous Lead Optimization projects supported by DMPK 0
Percent impact on timeline by DMPK support 0.1
Target cycle time (months) to achieve Lead Optimization 18
Target cycle time (months) to achieve Preclinical Development 24
Group size at 75% FTE efficiency 20
Group size at 50% FTE efficiency 40
aSee Experimental section for a detailed explanation of the control variables.
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“what if” scenarios to be tested with varying input para-
meters, thereby revealing potential areas of opportunity for
either improvement or optimization. Too many preclinical
candidates in a given time-frame could potentially stress
development resources and thereby increase downstream
cycle times. This, in turn, would ultimately adversely affect
overall productivity of the company in terms of NMEFigure 7 Simulation results using the assumptions outlined in
Table 1. Output values are the average number of preclinical
candidate compounds generated per year for a given combination
of chemists and biologists.launches per unit time [27]. Too few and gaps appear in
the clinical development pipeline that cannot be filled by
internal research and must be addressed through external
means such as in-licensing or joint ventures. Predicted
value and probability of technical success for the preclinical
candidates that emerge from the discovery pipeline are
critically important, certainly more so than simply the ab-
solute numbers that emerge. While the model does not ex-
plicitly take these particular parameters into account, the
assumption is made that the working group conducts those
evaluations as part of the decision-making process as
reflected in the attrition rates.
Inspection of Figure 7 indicates that growing a single
working group size beyond approximately 36 scientists
does not lead to a commensurate increase in productivity.
In fact, given the simulation assumptions listed in Table 1,
the maximum output per working group is predicted to be
0.86 preclinical candidates per year, which is a direct con-
sequence of the FTE efficiency correction factor. This par-
ticular simulation assumed that all lead optimization
projects were given standard priority. If all projects at the
lead optimization stage were given high priority, then the
predicted number of preclinical candidates per year is pre-
dicted to drop by one third (Figure 8). The simulation
therefore suggests that terminating earlier projects to sup-
port a high priority lead optimization campaign may help
achieve short-term objectives, but consistently doing so
will have a deleterious effect on long term productivity.
While this may not be preferable in all instances, sacrificing
longer term productivity to achieve short-term objectives
may be appropriate under certain circumstances. For ex-
ample, if there are first-in-class drug candidates with an
unproven MOA, or there are too many clinical candidatesFigure 8 Simulation results using the assumptions listed in
Table 1, except all projects at the lead optimization stage were
given high priority. Output values are average number of
preclinical candidate compounds generated per year for a given
combination of chemists and biologists.
Figure 10 (A) Monte Carlo simulation output values extracted
from the diagonal of Figure 8 (points). Output from Equation 6
(solid line). Under the simulation conditions, maximum output
occurs with 18 chemists. (B) Output from Equation 6 versus Monte
Carlo simulation output values extracted from the diagonal of
Figure 8 with linear regression line (r2 = 0.99).
Yu Journal of Cheminformatics 2012, 4:32 Page 9 of 14
http://www.jcheminf.com/content/4/1/32competing for development resources, then it may be ne-
cessary to review the milestone progression criteria and ad-
just them accordingly with an eye toward achieving clinical
POC as soon as possible.
Assuming a 1:1 ratio of standard and high priority lead
optimization campaigns along with the assumptions listed
in Table 1, the model predicts the maximum average
number of preclinical candidates per year to be around
0.67 (Figure 9). The diagonal leading edge of the contour
in Figure 9A marks the optimum combination of che-
mists and biologists for a given portfolio of drug discov-
ery programs, cycle times and project team sizes.
Extracting the values along the diagonal and plotting
output (average number of preclinical candidates per
year) as a function of the number of chemists affords a
biphasic curve [28] that can be empirically modeled
using Equation 6 (Figure 10). As before, maximum out-
put occurs with 18 chemists. Thus, for a given set of
assumptions, the impact of chemistry (or biology) group
size can be assessed in terms of overall predicted prod-
uctivity. Whether the analysis is chemistry-centric or
biology-centric will depend on the type of projects under
consideration. For example, projects targeting a best-in-
class drug candidate may need little exploratory biology
and strong chemistry support, whereas those targeting a
first-in-class drug may need extensive exploratory biology
and a small, but long-term chemistry commitment since
relatively little may be known to connect MOA with a
human disease state. Similarly, a total synthesis program
involving a structurally complex chemical lead may re-
quire a critical mass of chemists at the outset just to get
off the ground.
y ¼ t Aup
1þ Bup•e xCupDupð Þ
 Adn
1þ Bdn•e xCdnþDdnð Þ
Þ ð6Þ
Where:
x = number of chemistsFigure 9 Contour plot showing relationship between number of chem
priority and standard priority lead optimization campaigns. See Table











The relationship between FTE efficiency and predicted
output for a group of 36 scientists divided equally be-
tween chemists and biologists was investigated next,
again assuming a 1:1 ratio of standard to high priority
lead optimization projects. In this simulation, the values
of M and N were systematically varied with the limita-
tion that M must be greater than or equal to N+10. All
other parameters listed in Table 1 were held constant.
As expected, productivity is dependent on FTE effi-
ciency. For example, if FTE efficiency is 75% with a
group size of 20–30 and 50% with a group size of 55–65,
then the maximum average output is predicted to be
around 0.88 preclinical candidates per year (Figure 11).
If parameters M and N are sufficiently large, i.e., FTEists, biologists and predicted output for a 1:1 ratio of high
1 for all other assumptions. (A) Output defined by the average
er of active lead optimization projects per year.
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conditions the maximum average output could reach 1.2
preclinical candidates per year.
Inspection of Equation 1 indicates that project time-
lines (i.e. time to next milestone) are also affected by
FTE efficiency. As defined by the algorithm, two scien-
tists working at 50% FTE efficiency are equivalent to one
scientist working at 100% FTE efficiency. Thus, effi-
ciency and level of staffing work hand-in-hand by the
model to define the time to next milestone. Inspection
of the simulation output (data not shown) indicates that
at either low efficiency or low staffing the time to next
milestone can become unacceptably long. Consequent-
ly, the algorithm was modified such that projects that
have an elapsed time longer than a user-specified time
period are simply terminated and the scientists reas-
signed to other projects according to the priority out-
lined in Figure 3.
Repeating the simulation using cut-off values of 3.5
and 4.5 years for hit to lead and lead optimization activ-
ities, respectively, with the set of assumptions described
above yields the contour plots shown in Figure 12. In
addition to a slightly diminished maximum output (0.55
vs. 0.67), there is a sharp, seemingly paradoxical decline
in productivity that occurs at large group sizes (cf.
Figures 9A and 12A). This is due to the longer project
timelines associated with decreased FTE efficiency. If ef-
ficiency drops to a sufficiently low level, then many of
the lead optimization projects will reach their time limit
before the next milestone go/no-go decision. This effect
becomes very clear when a hard cut-off filter is applied
that restricts the lifetime for hit to lead and lead
optimization campaigns. Taken together, the modelFigure 11 Relationship between FTE efficiency parameters M, N
and predicted average number of preclinical candidates per
year for a working group of 36 scientists (18 chemists and
18 biologists) and 1:1 ratio of high priority to standard priority
lead optimization projects.predicts that there is an optimum working group size
beyond which productivity will either remain flat or ac-
tually decline in tandem with the number of viable lead
optimization campaigns. This number appears to be un-
affected by the priority given to lead optimization pro-
jects, which under conditions of the simulation is less
than 40 scientists. Increasing group size above this value
will lead to a proportional decrease in FTE efficiency,
which in turn will lead to lower productivity. In an at-
tempt to off-set the effect of low efficiency, the tendency
of individual project teams might be to seek an increase
in membership. If granted, however, this would lead to
fewer projects the working group can support, thereby
resulting in fewer preclinical candidates to ultimately
emerge from the discovery pipeline.
Repeating the FTE efficiency simulation (see Figure 11)
with 36 scientists as described earlier, but using lifetime
cut-off values of 3.5 and 4.5 years for hit to lead and lead
optimization campaigns, respectively, afforded very simi-
lar results where the maximum output in both cases is
predicted to be around 1 preclinical candidate per year
on average. However, differences were noted, particularly
at lower FTE efficiency (Figure 13). Smaller values of
M and N lengthen project timelines, thereby giving
rise to campaigns that run the risk of premature termina-
tion. In this regard, very little differences were noted at
the higher FTE efficiency range (i.e., larger values of M
and N).
Modifying the conditions of the simulation whereby
only certain types of projects are undertaken allows the
ratio of chemists to biologists to be assessed. As
expected, the optimal ratio of biologists to chemists was
shifted upward when projects that require greater ex-
ploratory biology were created (Figure 14). Exceeding
the optimal number of chemists in the group did not
lead to greater output since under those conditions pro-
jects became biology rate-limited. Conversely, for pro-
jects that require greater chemistry support adding more
biologists to the working group would not lead to an in-
crease in productivity as projects in that case would be-
come chemistry rate-limited. Thus, for a given ratio of
chemists and biologists there is an optimum combin-
ation of project types that can be supported.
Project team size requirements can exert a significant
impact on productivity. As team size grows, project
numbers shrink, resulting in fewer preclinical candidates
to emerge from the discovery pipeline. As an example,
the size of lead optimization project teams was varied
from 6 to 12 scientists, equally split between chemists
and biologists. As before, a 1:1 ratio of high priority to
standard priority was assumed along with assigning
M=40 and N=20. All other parameters were held con-
stant (Table 1). In this simulation, the working group
size was allowed to span the range of 10–40 scientists
Figure 12 Contour plot showing relationship between number of chemists, biologists and predicted output for a 1:1 ratio of high
priority and standard priority lead optimization campaigns. Cut-off values of 3.5 and 4.5 years were applied for hit to lead and lead
optimization activities, respectively, after which the projects were simply terminated. See Table 1 for all other assumptions. (A) Output as defined
by the average number of preclinical candidates per year. (B) Output defined by the average number of active lead optimization projects per year.
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ical candidates was captured. As illustrated in Figure 15,
there is a clear decline in maximum productivity as pro-
ject team size requirements grow.
The types of projects undertaken by a working group
can also affect output, albeit to a much lesser extent
than project team size. Assuming a 1:1 ratio of high pri-
ority to standard priority lead optimization projects, a
fixed FTE efficiency of 80% and the simulation para-
meters listed in Table 1, the output for 36 scientists (18
chemists and 18 biologists) as a function of percent
follow-on projects versus percent chemistry/biology
driven projects was predicted (Figure 16). Higher outputFigure 13 Productivity difference map between two FTE
efficiency simulations that systematically varied M and N for
18 chemists and 18 biologists (1:1 ratio of high priority to
standard priority lead optimization projects). The only difference
between the two runs is the presence or absence of project lifetime
cut-off values applied for hit to lead and lead optimization activities
(3.5 and 4.5 years, respectively). See Table 1 for all other
assumptions. The values along the z-axis represent the difference in
predicted productivity output between the two simulations, where
productivity is slightly higher in the absence of timeline constraints.was noted when a larger percentage of follow-on pro-
jects was undertaken. In this analysis, little if any differ-
ences were noted when varying the percentage of
chemistry driven projects.
The FTE efficiency simulation with two relatively large
working groups consisting of 60 and 80 scientists again
equally split between chemists and biologists was run to
afford the results shown in Figure 17. At sufficiently
high FTE efficiency, the maximum output predicted for
these two particular groups is 1.9 and 2.5 preclinical
candidates per year, respectively. Based on these results,
the next series of simulations were run with the FTE ef-
ficiency parameters N and M set to 100 and 150,
respectively.
To evaluate the number of preclinical candidates to
emerge in unit time, two simulations were run withFigure 14 Contour plot showing relationship between number
of chemists, biologists and predicted preclinical candidate
output for biology-driven projects. Cut-off values of 3.5 and
4.5 years were applied for hit to lead and lead optimization
activities, respectively, after which the projects were simply
terminated. See Table 1 for all other assumptions.
Figure 15 Relationship between lead optimization project team
size and maximum number of preclinical candidates produced
by a working group of 10–40 scientists. See text and Table 1 for
simulation parameters.
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tions described above. For a relatively small working
group of 20 scientists the output is predicted to be 0.6
preclinical candidates per year on average. For a larger
group of 80 scientists the predicted output is around 2.
Plotting number of preclinical candidates as a function
of time for both working groups reveals that compounds
are predicted to pass the candidate selection milestone
and enter preclinical development at irregular intervals
(Figure 18). This appears to be independent of working
group size. For the 20 and 80 member groups, the num-
ber of preclinical candidates in any given year is pre-
dicted to range from 0–3 and 0–9, respectively. The
wide variation in both cases suggests that workingFigure 16 Relationship between percent chemistry-driven
projects versus percent follow-on projects in terms of
preclinical candidate output for a working group of
18 chemists and 18 biologists. See text and Table 1 for simulation
parameters.groups, regardless of size, can experience prolonged
trough periods of low apparent output followed by peri-
ods of high productivity as measured by the number of
preclinical candidates to emerge from the discovery
pipeline. This is likely a consequence of projects moving
at different speeds through the milestone system as a re-
sult of different project priorities and resource support
limitations. The model therefore predicts that careful
project management will be necessary to match discov-
ery output over time with downstream development re-
source capacity.
A careful analysis and evaluation of working group
size, project team size, cycle time and FTE efficiency are
important steps to better understand the differences, if
any, that may exist between current output and perform-
ance expectations. For example, if simulations suggest
that a target output of 2 preclinical candidates per year
for a particular working group might not be realistic
even under optimal conditions for a specific set of
assumptions, then the team may wish to consider ways
to enhance production that may involve increasing
working group size or changing resource deployment
strategies. Since the objective of drug discovery is to feed
the drug development pipeline and achieve clinical POC
as soon as possible, then simulations may help define
where specific discovery milestones should be placed
relative to each other. This will undoubtedly impact
transition probabilities and redefine resource needs de-
pending on the type of programs undertaken in connec-
tion with the working group’s strategic plan. Other
opportunities may include resource sharing with other
working groups to identify compounds with a similar
MOA, but different disease targets or it could involve in-
ternal or external collaborations that take advantage of
specific enabling technologies. An alternative to expand-
ing a single working group might be to create and grow
a separate working group altogether. This would obviate
much of the FTE overhead associated with a large group,
but still allow overall productivity to increase commen-
surate with the number of scientists.
To benchmark working group performance, the abso-
lute maximum output for a group of 18 chemists and 18
biologists operating with an FTE efficiency of 100% and
all milestone transition probabilities set to 100% was
simulated. In this experiment, all lead optimization pro-
jects received full DMPK support, and a maximum life-
time of 3.5 and 4.5 years for hit to lead and lead
optimization projects, respectively, was used. All other
parameters were set to those listed in Table 1. Under
these conditions, the model predicts that a maximum of
2 preclinical candidates per year would be generated by
such a department, division or specialty center. The
average output for an identical sized working group, but
operating with a fixed FTE efficiency of 80% and all
Figure 17 Relationship between FTE efficiency parameters M, N and predicted average number of preclinical candidates per year
(1:1 ratio of high priority to standard priority lead optimization projects with hit to lead and lead optimization project lifetime cutoff
values of 3.5 and 4.5 years, respectively. (A) Working group of 60 scientists (30 chemists and 30 biologists). (B) Working group of 80 scientists
(40 chemists and 40 biologists).
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by Paul and co-workers1 is predicted to be 1 preclinical
candidate per year. By assuming that all lead
optimization projects have high priority, the output
drops slightly to 0.8. On the other hand, if all projects
are mandated to have an on-going shared resource
“back-up” series, then output is predicted to increase
somewhat to 1.3 preclinical candidates per year. Thus,
the model allows working group productivity to be
assessed in the context of multiple variables, including
FTE efficiency, project priority handling, types of pro-
jects, and milestone transition probabilities, factors that
are closely tied to the working group’s overall research
strategy. If discovery DMPK support becomes rate-
limiting then productivity will incrementally decrease
depending on the number of lead optimization projects
that can simultaneously be supported.
Conclusion
The productivity challenge facing the pharmaceutical in-
dustry is complex and multifactorial. While early discov-
ery marks just the beginning of a very long and costlyFigure 18 Time chart showing simulated preclinical candidate output
following: (A) 10 chemists and 10 biologists with an average output o
output around 2.process of bringing an NME to market, it plays a critical
role in helping to maintain a robust clinical development
pipeline. Obviously, without preclinical candidates there
would be no clinical POC studies. Successfully refocus-
ing effort and resources earlier in the drug development
process will require a strong portfolio of quality preclin-
ical candidates that have a reasonable probability of
technical success. In that regard, the Monte Carlo simu-
lation suggests that attempting to improve drug discov-
ery productivity by simply increasing the size of existing
working groups may not necessarily be the best solution.
On the contrary, the model predicts that for a given
portfolio of discovery projects there is an optimum
number of scientists, beyond which productivity in
terms of preclinical candidates will remain flat. In such
circumstances, establishing and growing a separate
working group (i.e. a separate business unit, division or
therapeutic specialty center) may be a more effective
strategy, consistent with the concept of decentralized de-
cision-making. For example, by creating business units
that function more like biotech companies in terms of
size, autonomy and accountability, but with theas a function of year for a working group comprised of the
f 0.6. (B) 40 chemists and 40 biologists with an average
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http://www.jcheminf.com/content/4/1/32infrastructure and support of a large organization, FTE
overhead associated with large groups may be substan-
tially reduced. While there are many factors that impact
how discovery projects progress through a milestone
system, working group size and FTE efficiency are
among the most amenable to change in order to
optimize overall performance. Simulations also predict
that the frequency of compounds to successfully pass
the candidate selection milestone as a function of time
will be irregular, with projects entering preclinical devel-
opment in clusters marked by periods of low apparent
productivity. Thus, the model may be useful as a tool to
facilitate analysis of historical growth and achievement
over time, help gauge current working group progress
against future performance expectations, and provide
the basis for dialogue regarding working group best
practices and resource deployment strategies.
Acknowledgement
The author wishes to thank Dr. Ted Suh for his support, insight and helpful
suggestions.
Received: 10 September 2012 Accepted: 23 November 2012
Published: 27 November 2012
References
1. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR,
Schacht AL: How to improve R&D productivity: the pharmaceutical
Industry’s grand challenge. Nature Rev Drug Discov 2010, 9:203–214.
2. Pammolli F, Magazzini L, Riccaboni M: The productivity crisis in
pharmaceutical R&D. Nature 2011, 10:428–438.
3. Pyzdek T: In The Six sigma handbook: The complete guide for greenbelts,
blackbelts, and managers of All levels, 2nd revised edition. New York:
McGraw-Hill; 2003.
4. Johnstone C, Pairaudeau G, Pettersson JA: Creativity, innovation and lean
sigma: a controversial combination? Drug Discov Today 2011, 16:50–57.
5. Chow SC, Chang M: Adaptive Design Methods in Clinical Trials - A
Review. Orphanet J Rare Dis 2008, 3:11.
6. Orloff J, Douglas F, Pinheiro J, Levinson S, Michael BM, Chaturvedi P, Ette E,
Gallo P, Hirsch G, Mehta C, Patel N, Sabir S, Springs S, Stanski D, Evers MR,
Fleming E, Singh N, Tramontin T, Golub H: The future of drug
development: advancing clinical trial design. Nat Rev Drug Discov 2009,
8:949–957.
7. Chang M: Monte Carlo simulation for the pharmaceutical industry.
Boca Raton: CRC Press; 2011.
8. Jones B: The burden of knowledge and the ‘death of the renaissance
Man’: is innovation getting harder? Rev Econ Stat 2009, 76:283–317.
9. Nonaka I: The Knowledge-Creating Company. Harvard Bus Rev 1991,
69:96–104.
10. Nonaka I: A dynamic theory of organizational knowledge creation.
Organ Sci 1994, 5:14–37.
11. Libby R, Blashfield RK: Performance of a composite as a function of the
number of judges. Organ Behav Hum Perform 1978, 21:121–129.
12. Hill GW: Group versus individual performance: Are N+1 heads better
than One? Psychol Bull 1982, 91:517–539.
13. Garnier JP: Rebuilding the R & D engine in Big pharma. Harvard Bus Rev
2008, 86:68–76.
14. Lamm H, Trommsdorff G: Group versus individual performance on tasks
requiring ideational proficiency (brainstorming): a review. Eur J Soc
Psychol 1973, 3:361–387.
15. Mullen B, Johnson C, Salas E: Productivity loss in brainstorming groups: a
meta-analytic integration. Basic Appl Soc Psych 1991, 12:3–23.
16. Berg S: Condorcet's Jury theorem. Dependence Among Jurers. Soc Choice
Welf 1993, 10:87–95.
17. Berg S: Condorcet's Jury theorem revisited. Eur J Polit Econ 1993,
9:437–446.18. Berend D, Parous J: When is Condorcet's jury theorem valid? Soc Choice
Welf 1998, 15:481–488.
19. Genest C, Zidek V: Combining probability distributions: a critique and an
annotated bibliography. Stat Sci 1986, 1:114–148.
20. Adler FP: Relationships between organization size and efficiency.
Manage Sci 1960, 7:80–84.
21. Van de Ven AH, Delbecq AL: Nominal versus interacting group processes
for committee decision making. Acad Manage J 1971, 14:203–212.
22. Grofman B, Feld SL: Group size and the performance of a composite
group majority: statistical truths and empirical results. Organ Behav Hum
Perform 1984, 33:350–359.
23. Woolley AW, Chabris CF, Pentland A, Hashmi N, Malone TW: Evidence for a
collective intelligence factor in the performance of human groups.
Science 2010, 330:686–688.
24. Rogers EM: Diffusion of innovations. 5th edition. New York: Simon and
Schuster; 2003.
25. Cuatrecasas P: Drug discovery in jeopardy. J Clin Invest 2006,
116:2837–2842.
26. OriginPro, version 8.6. Northampton, MA: Origin Lab Corporation; 2012.
27. Little JDC: A proof of the queuing formula: L=λW. Oper Res 1961,
9:383–387.
28. Beckon WN, Parkins C, Maximovich A, Beckon AV: A general approach to
modeling biphasic relationships. Environ Sci Technol 2008, 42:1308–1314.
doi:10.1186/1758-2946-4-32
Cite this article as: Yu: Simulating the drug discovery pipeline: a Monte
Carlo approach. Journal of Cheminformatics 2012 4:32.Open access provides opportunities to our 
colleagues in other parts of the globe, by allowing 
anyone to view the content free of charge.
Publish with ChemistryCentral and every
scientist can read your work free of charge
W. Jeffery Hurst, The Hershey Company.
available free of charge to the entire scientific community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central
yours     you keep the copyright
Submit your manuscript here:
http://www.chemistrycentral.com/manuscript/
